Submitted for Publication: February 20, 2014; final revision received June 2, 2014; accepted June 30, 2014.
Published Online: October 1, 2014. doi:10.1001/jamapsychiatry.2014.1582.
Study concept and design: Konopaske, Coyle, Benes.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Konopaske, Lange, Coyle.
Critical revision of the manuscript for important intellectual content: Konopaske, Coyle.
Statistical analysis: Konopaske, Lange.
Obtained funding: Konopaske, Coyle.
Administrative, technical, or material support: Benes.
Study supervision: Benes.
Conflict of Interest Disclosures: Dr Coyle served as a consultant for Abbvie Laboratories and En Vivo. No other disclosures were reported.
Funding/Support: This study was funded by grants 1K08MH087640-01A1, R01MH05190, P50MH0G0450, and R24MH068855 from the National Institute of Mental Health and by the William P. and Henry B. Test Endowment.
Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, or interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: Dr Coyle is the Editor of JAMA Psychiatry but was not involved in the editorial review or the decision to accept the manuscript for publication.
Previous Presentation: Preliminary data from the manuscript were presented at the American College of Neuropsychopharmacology; December 10, 2013; Hollywood, Florida.
Additional Contributions: We thank Susan Konopaske, MAT, for reviewing the manuscript. She did not receive any financial compensation.